NU 6140 A highly cell-permeable purine compound that acts a ATP-competitive inhibitor of Cdks

NU 6140 (CAS 444723-13-1)

NU 6140 | CAS 444723-13-1 is rated 5.0 out of 5 by 1.
  • y_2019, m_7, d_14, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202531, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 154ms
  • REVIEWS, PRODUCT
Synonym: 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; Cdk2 Inhibitor IV
Application: A highly cell-permeable purine compound that acts a ATP-competitive inhibitor of Cdks
CAS Number: 444723-13-1
Purity: ≥95%
Molecular Weight: 422.52
Molecular Formula: C23H30N6O2
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Cdk2 Inhibitor IV, NU6140 is a highly cell-permeable purine compound that displays anticancer properties and acts as a selective and ATP-competitive inhibitor of Cdks (IC50 = 6.6 μM, 0.41 μM, 5.5 μM, 15 μM and 3.9 μM for Cdc2 (Cdk1)/cyclin B, Cdk2/cyclin A, Cdk4/cyclin D, Cdk5/p25 and Cdk7/cyclin H, respectively). Cdk2 Inhibitor IV, NU6140 has been shown to cause cell cycle arrest at the G2/M phase and induce apoptosis by activating caspases and down-regulating survivin. Cdk2 Inhibitor IV, NU6140 has also been shown to synergistically potentiate paclitaxel cytotoxicity and apoptotic response in HeLa and OAW42 cells.


References

1. Pennati, M., et al. 2005. Mol. Cancer Ther. 4: 1328-1337. PMID: 16170024

Physical State :
Solid
Solubility :
Soluble in DMSO (10 mg/ml), and ethanol (100 mM).
Storage :
Store at 4° C
Melting Point :
~288.53° C (Predicted)
Boiling Point :
~707.8° C at 760 mmHg (Predicted)
Density :
~1.2 g/cm3 (Predicted)
Refractive Index :
n20D 1.63 (Predicted)
IC50 :
Cdk1/cyclin B: IC50 = 6.6 µM; Cdk2/cyclin A: IC50 = 0.41 µM; Cdk4/cyclin D: IC50 = 5.5 µM; Cdk5/p25: IC50 = 15 µM; Cdk7/cyclin H: IC50 = 3.9 µM; Interferon-induced, double-stranded RNA-activated protein kinase: IC50 = 2 µM (human)
pK Values :
pKa: 9.14, pKb: 3.17
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
10202471
MDL Number :
MFCD09264153
SMILES :
CCN(CC)C(=O)C1=CC=C(C=C1)NC2=NC3=C(C(=N2)OCC4CCCCC4)NC=N3

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 84ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from A decrease in survivin expression in HeLa A decrease in survivin expression in HeLa cells was observed by WB when comparing untreated and NU 6140 and Purvalanol A treated cells. -SCBT QC
Date published: 2015-02-06
  • y_2019, m_7, d_14, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202531, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 4ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.